Advances in genetic polymorphisms of antiplatelet drugs on platelet reactivity
10.13303/j.cjbt.issn.1004-549x.2025.10.018
- VernacularTitle:抗血小板药物基因多态性对血小板反应性的研究进展
- Author:
Xuewei DENG
1
;
Jieling LIANG
1
;
Yaming WEI
2
;
Zhaohu YUAN
2
Author Information
1. Department of Blood Transfusion, Zhaoqing First Peoples Hospital, Zhaoqing 526040, China
2. Department of Blood Transfusion, Guangdong Engineering Research Centre of Precise Transfusion, Guangzhou First Peoples Hospital, Guangzhou 510180, China; Research Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou 510180, China
- Publication Type:Journal Article
- Keywords:
platelet reactivity;
antiplatelet agents;
gene polymorphism;
aspirin;
clopidogrel;
protease-activated receptor antagonists
- From:
Chinese Journal of Blood Transfusion
2025;38(10):1413-1420
- CountryChina
- Language:Chinese
-
Abstract:
Cardiovascular diseases (CVD s) remain the leading cause of death globally, constituting a serious threat to human health. As the cornerstone of primary and secondary prevention, antiplatelet therapy exhibits substantial individual variability in treatment efficacy, presenting a major challenge in clinical practice. Recent investigations have revealed that the diversity of platelet responses not only bears a close association with the risks of thrombotic/bleeding events but also serves as a pivotal breakthrough point for realizing precision medication. This paper systematically reviews the impact of genetic polymorphisms on platelet reactivity in response to three commonly used antiplatelet drugs: aspirin, P2Y12 receptor antagonists, and protease-activated receptor antagonists. It emphasizes the importance of multidimensional assessment in individualized treatment and highlights the critical role of precision antiplatelet therapy strategies.
